[1]赵小艳,朱丽群,曹松梅,等.房颤患者长期口服抗凝药物管理的最佳证据总结[J].军事护理,2022,39(12):70-74.[doi:10.3969/j.issn.2097-1826.2022.12.018]
　ZHAO Xiaoyan,ZHU Liqun,CAO Songmei,et al.Summary of Best Evidence for Long-Term Oral Anticoagulant Management in Patients with Atrial Fibrillation[J].Nursing Journal Of Chinese People's Laberation Army,2022,39(12):70-74.[doi:10.3969/j.issn.2097-1826.2022.12.018]
点击复制

房颤患者长期口服抗凝药物管理的最佳证据总结
分享到：

《军事护理》[ISSN:2097-1826/CN:31-3186/R]

卷:
39
期数:
2022年12期
页码:
70-74
栏目:
循证护理
出版日期:
2022-12-15

文章信息/Info

Title:
Summary of Best Evidence for Long-Term Oral Anticoagulant Management in Patients with Atrial Fibrillation
文章编号:
2097-1826(2022)12-0070-05
作者:
赵小艳1; 朱丽群2; 曹松梅2; 包磊3; 汪淑华4; 封蔓5; 刘君1
(1.江苏大学附属医院 心内科,江苏 镇江 212001; 2.江苏大学附属医院 护理部; 3.江苏大学附属医院 手术室; 4.江苏大学医学院,江苏 镇江 212013; 5.江苏大学附属医院 胃肠外科)
Author(s):
ZHAO Xiaoyan1; ZHU Liqun2; CAO Songmei2; BAO Lei3; WANG Shuhua4; FENG Man5; LIU Jun1
(1.Department of Cardiology,Affiliated Hospital of Jiangsu University,Zhenjiang 212001,Jiangsu Province,China;2.Department of Nursing, Affiliated Hospital of Jiangsu University;3.Operating Room,Affiliated Hospital of Jiangsu University;4.School of Medicine,Jiangsu University,Zhenjiang 212013,Jiangsu Province,China;5.Department of Gastrointestinal Surgery,Affiliated Hospital of Jiangsu University)
关键词:
房颤;  口服抗凝;  循证护理
Keywords:
atrial fibrillation;  oral anticoagulant;  evidence-based nursing
分类号:
R47
DOI:
10.3969/j.issn.2097-1826.2022.12.018
文献标志码:
A
摘要:
目的 总结国内外房颤患者长期口服抗凝药物管理的最佳证据,为临床提供参考。方法 采用 PIPOST 构建循证问题,计算机检索 BMJ最佳临床实践、Up To Date、JBI、知网等数据库中关于房颤患者口服抗凝药物管理的证据。对文献质量进行评价,并对纳入文献进行资料提取和分析。结果 共纳入11篇文献,形成28条最佳证据,包括组织管理、动态评估、依从性管理、抗凝安全监测、心理干预、健康教育及随访等6个方面。结论 总结了房颤患者长期口服抗凝药物管理的最佳证据,可为医护人员提高房颤患者抗凝管理质量提供循证依据。
Abstract:
Objective To summarize the best evidence of long-term oral anticoagulant drug management in patients with atrial fibrillation(AF)at home and abroad, and provide reference for clinical practice. Methods Using PIPOST to construct evidence-based questions,we searched BMJ Best Practice,Up To Date, JBI,CNKI and other databases for evidences of oral anticoagulant management in patients with AF. The quality of the literature was evaluated, and the data were extracted and analyzed. Results A total of 11 literatures were selected,28 best evidences in 6 aspects were summarized,including organizational management,dynamic assessment,medication compliance management,safety monitoring of anticoagulants,psychological intervention,patient education and follow-up.Conclusions This study summarizes the best evidence of long-term oral anticoagulant management in patients with AF,which can provide evidence-based evidence for medical staff to improve the quality of anticoagulant management.

参考文献/References:

[1] 马长生.2019年心房颤动治疗新进展[J].临床心血管病杂志,2019,35(11):5.
[2] SHEHAB N,LOVEGROVE M C,GELLER A I,et al.US emergency department visits for outpatient adverse drug events,2013-2014 [J].JAMA,2016,316(20):2115-2125.
[3] The Joint Commission.2021 National Patient Safety Goals[EB/OL].[2022-03-30].https://www.jointcommission.org/standards/national-patient-safety-goals/-/media/b35ba0b4b9754c6dbafdb1f86e152e5c.ashx.
[4] 董丽.基于循证的抗凝风险教育对于房颤患者抗凝知识,疾病不确定感及抗凝治疗依从性的影响[D].苏州:苏州大学,2019.
[5] 陆洋,傅巧美.心脏瓣膜置换术后患者抗凝治疗依从性的调查分析[J].解放军护理杂志,2016,33(8):62-64.
[6] 郑英丽,丁征.抗凝(栓)门诊标准操作规程专家共识[J].中国循环杂志,2019,34(10):944-950.
[7] 周英凤,顾莺,胡雁,等.JBI循证卫生保健中心关于不同类型研究的质量评价工具——干预性研究的质量评价[J].护士进修杂志,2018,33(1):24-26.
[8] The Appraisal of Guidelines for Research and Evaluation.AGREE II-users manual and 23-item instrument[EB/OL].[2022-03-15].https://www.agreetrust.org/about-the-agree-enterprise/intro-duction-to-agree-ii/.
[9] 王春青,胡雁.JBI证据预分级及证据推荐级别系统(2014版)[J].护士进修杂志,2015,30(11):964-967.
[10]ARTI N,BHARAT K.Atrial fibrillation [EB/OL].[2022-04-10].https://bestpractice.bmj.com/topics/zh-cn/1.
[11]LAWRENCE L K.Direct oral anticoagulants doacs and parenteral direct acting anticoagulants dosing and adverse effects [EB/OL].[2022-04-10].https://www.uptodate.cn/contents/zh-Hans/ direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects.
[12]RUSSELL D H,MSCDAVID A G,SARA R V,et al.Biology of warfarin and modulators of INR control [EB/OL].[2022-04-10].https://www.uptodate.cn/contents/zh-Hans/biology-of-warfarin-and-modulators-of-inr-control.
[13]DAVID A G,CROWTHER M.Risks and prevention of bleeding with oral anticoagulants [EB/OL].[2022-04-10].https://www.uptodate.cn/contents/zh-Hans/risks-and-prevention-of-bleeding-with-oral-anticoagulants.
[14]HINDRICKS G,POTPARA T,DAGRES N,et al.2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2021,42(5):373-498.
[15]LIP G Y H,BANERJEE A,BORIANI G,et al.Antithrombotic therapy for atrial fibrillation:CHEST guideline and expert panel report[J].Chest,2018,154(5):1121-1201.
[16]HELEN W S.Clinical guide for the management of anticoagulant services during the coronavirus pandemic.[EB/OL].[2022-04-12].https://www.nice.org.uk/media/default/about/covid-19/specialty-guides/ specialty-guide-anticoagulant-services-and-coronavirus.pdf.
[17]STEFFEL J,COLLINS R,ANTZ M,et al.2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J].Europace,2021,23(10):1612-1676.
[18]PORRITT K.Atrial fibrillation:patient education[EB/OL].[2022-04-10].https://ovidsp.dc2.ovid.com/ovid-b/ovidweb.cgi?&S=PFEPFPHGMHEBKKODJPNJPHDGLAJBAA00&Complete+Reference=S.sh.18%7c1%7c1&Counter5=SS_view_found_complete%7cJBI16145%7cjbi%7cjbidb%7cjbi&Counter5Data=JBI16145%7cjbi%7cjbidb%7cjbi.
[19]DIANA A G,YING X G,TZE-FAN C,et al.Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism:a position paper from the ESC Working Group on Thrombosis,in collaboration with the European Heart Rhythm Association,the Association for Acute Cardio-Vascular Care and the Asia-Pacific Heart Rhythm Society[J/OL].[2022-03-20].https://academic.oup.com/europace/advance-article/doi/10.1093/europace/euac020/6551877?login=true.DOI:10.1093/europace/euac020.
[20]张萍,朱俊,胡大一.心房颤动基层诊疗指南(2019年)[J].中华全科医师杂志 2020,19(6):465-473.
[21]GUO A,LANE D A,CHEN Y,et al.Regular bleeding risk assessment associated with reduction in bleeding outcomes:the mAFA-II randomized trial [J].Am J Med,2020,133(10):1195-1202.
[22]GOODMAN-CASANOVA J M,GUZMAN-PARRA J,GUERRERO G,et al.TV-based assistive integrated service to support European adults living with mild dementia or mild cognitive impairment(TV-AssistDem):study protocol for a multicentre randomized controlled trial[J/OL].[2022-03-20].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731559/.DOI:10.1186/s12877-019-1267-z.
[23]FAUCHIER L,BISSON A,CLEMENTY N,et al.Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation [J].Am Heart J,2018,198:39-45.
[24]张永春,李业涛,谢贵华,等.抗凝自我管理手机APP软件的研制与应用[J].护理研究,2020,34(10):1844-1845.
[25]LIEN D,JOHAN V,PIETER K,et al.Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation [J].Eur Heart J,2018,39(16):1394-1403.
[26]GLADSTONE D J,GEERTS W H,DOUKETIS J,et al.How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation:a practice tool endorsed by thrombosis Canada,the Canadian Stroke Consortium,the Canadian Cardiovascular Pharmacists Network,and the Canadian Cardiovascular Society[J].Ann Intern Med,2015,163(5):382-385.

备注/Memo

备注/Memo:
【 收稿日期 】 2022-04-22 【 修回日期 】 2022-10-22
【 基金项目 】 江苏省老年健康科研项目(LK2021026); 镇江“金山英才”高层次领军人才培养项目
【 作者简介 】 赵小艳,硕士,副主任护师,从事心血管临床护理
【 通信作者 】 朱丽群,电话:0511-85088032
更新日期/Last Update: 2022-12-15